NEWS

July 29, 2010	Bio-path Holdings announces Dosing of First Patient in a Phase I Clinical Trial of its Liposomal Grb-2 Cancer Drug Candidate
June 4, 2010	Bio-Path Holdings Signs Equity Financing Deal Equity Purchase Agreement With Institutional Investor Lincoln Park Capital to Provide Up to $7 Million In New Capital
March 12, 2010	FDA Allows IND For Bio-Path Holdings' Liposomal Grb-2 Company to Commence Phase I Clinical Trial Of Its Cancer Drug To Treat CML, AML, ALL, & MDS
December 14, 2009	Bio-Path Holdings, Inc. Completes Private Placement Capital Raise and Provides Update to IND Status
November 2, 2009	Bio-Path Holdings, Inc. Operations Update
September 22, 2009	Bio-Path Holdings, Inc. Announces Plans To Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center
June 23, 2009	Bio-Path Holdings, Inc. Provides Operations Update and Overview Of New Targeting Technology
June 6, 2009	Proxy Statement and Proxy
April 14, 2009	Bio-Path Holdings, Inc. Announces Clinical Support Agreement With ACORN And Names Bradley G. Somer, M.D., As Medical Officer For Phase I Clinical Trial
December 10, 2008	Letter To Shareholders
December 3, 2008	Bio-Path Holdings, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program
November 17, 2008	Bio-Path Holdings, Inc. Announces the Signing of a Drug Manufacturing Agreement with Althea Technologies, Inc.
June 23, 2008	Bio-Path Holdings Announces Dr. Hans A. de Hann Has Joined The Company As Medical Director
March 3, 2008	Bio-Path Becomes a Publicly Traded Company

Copyright 2008, Bio-Path Holdings, Inc., All rights reserved.